AcuCort has received its first order of the oral film Zeqmelit®. The order value will have a significant positive impact on the company’s financial results.
– This order signifies a crucial milestone in AcuCort’s history, says Jonas Jönmark, CEO of AcuCort.
Zeqmelit®, a rapidly dissolving oral film administered on the tongue for the treatment of severe to acute allergies, is in an intensive commercialization phase. Now, the first order has been received. The purchaser is Unimedic Pharma, also responsible for Zeqmelit® sales in the Nordic region. The order includes Zeqmelit® in its three strengths: 4, 6, and 8mg. The order value will significantly boost AcuCort's results for the current quarter.
– It's very gratifying to know that Zeqmelit® will soon be available in pharmacies in the Nordics, providing individuals with severe to acute allergies access to better treatment than before, says Jonas Jönmark.
The order signifies AcuCort's transition from being a developmental company to becoming a commercial pharmaceutical company.
– It's a historic milestone, and it feels very rewarding. We estimate that the order covers the initial demand in the first phase of the launch in the Nordics, says Jonas Jönmark.
Production has commenced. Zeqmelit®, a prescription medicine based on the well-known corticosteroid substance dexamethasone, will be available in pharmacies starting from the summer of 2024.
Facts about Zeqmelit®
• Approved for the treatment of severe to acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for patients with COVID-19 experiencing respiratory distress and requiring oxygen therapy.
• A thin, rapidly dissolving, user-friendly oral film that melts on the tongue within 10 – 15 seconds.
• Patients do not need access to water to use the product.
• The oral film is packaged in a small and convenient size, similar to a business card. • Approved in Sweden, Denmark, Norway, and Finland.
• 72 percent of the patient group would prefer an oral film over tablet treatment for a severe allergic reaction according to a survey study.
This information constitutes information that AcuCort is obligated to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the above contact person's provision, on 2024-2-27, 8.30 CET.
For further information:
Jonas Jönmark, CEO AcuCort AB
Tel: +46 70 3655400
Email: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.